Developer of AI-based technology for the discovery of peptide drug candidates. The platform's technology is an algorithm that assists in protein-protein interface and peptide-protein interface enabling the design of binding peptides, agonists, and antagonists that are intended to block protein-protein interactions. It analyzes the target surface surrounding the desired binding area and then performs a design process to provide a peptide library with optimal binding affinity. Founded in 2011, headquartered in Jerusalem, Israel. The company has raised $7.6M at the Series A stage backed by investors including Chartered High Tech, Chartered Group. Operating in Life Sciences > Genomics, HealthTech > Life Sciences Tech.
← All startups
Pepticom
Series ADeveloper of AI-based technology for the discovery of peptide drug candidates. The platform's technology is an algorithm that assists in protein-protein interface and peptide-protein interface enabling the design of binding peptides, agonists, and antagonists that are intended to block protein-protein interactions. It analyzes the target surface surrounding the desired binding area and then performs a design process…
About
Business model
Life Sciences Tech > Research & Development > Drug Discovery > Proteomics,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Institutional investors
Chartered High TechChartered Group
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Browse all funds in our directory — active VCs and growth investors by stage and sector.